93 related articles for article (PubMed ID: 24468131)
1. Pharmacological profiles of acute myeloid leukemia treatments in patient samples by automated flow cytometry: a bridge to individualized medicine.
Bennett TA; Montesinos P; Moscardo F; Martinez-Cuadron D; Martinez J; Sierra J; García R; de Oteyza JP; Fernandez P; Serrano J; Fernandez A; Herrera P; Gonzalez A; Bethancourt C; Rodriguez-Macias G; Alonso A; Vera JA; Navas B; Lavilla E; Lopez JA; Jimenez S; Simiele A; Vidriales B; Gonzalez BJ; Burgaleta C; Hernandez Rivas JA; Mascuñano RC; Bautista G; Perez Simon JA; Fuente Ade L; Rayón C; Troconiz IF; Janda A; Bosanquet AG; Hernandez-Campo P; Primo D; Lopez R; Liebana B; Rojas JL; Gorrochategui J; Sanz MA; Ballesteros J
Clin Lymphoma Myeloma Leuk; 2014 Aug; 14(4):305-18. PubMed ID: 24468131
[TBL] [Abstract][Full Text] [Related]
2. Ex-vivo drug testing predicts chemosensitivity in acute myeloid leukemia.
Lin L; Tong Y; Straube J; Zhao J; Gao Y; Bai P; Li J; Wang J; Wang H; Wang X; Huang S; Xu W; Song X; Li L
J Leukoc Biol; 2020 May; 107(5):859-870. PubMed ID: 32293060
[TBL] [Abstract][Full Text] [Related]
3. A method comparison study of flow cytometry and cytomorphology to determine the percentages of blasts in patients with acute leukemia after induction and consolidation chemotherapy.
Wongprajun S; Auewarakul CU
J Med Assoc Thai; 2010 Jan; 93 Suppl 1():S157-64. PubMed ID: 20364570
[TBL] [Abstract][Full Text] [Related]
4. Pharmacodynamic monitoring of molecular-targeted agents in the peripheral blood of leukemia patients using flow cytometry.
Hedley DW; Chow S; Goolsby C; Shankey TV
Toxicol Pathol; 2008 Jan; 36(1):133-9. PubMed ID: 18337231
[TBL] [Abstract][Full Text] [Related]
5. Pretreatment prognostic factors for overall survival in primary resistant acute myeloid leukemia.
Colovic N; Tomin D; Vidovic A; Suvajdzic N; Jankovic G; Palibrk V; Djunic I; Djurasinovic V; Virijevic M
Biomed Pharmacother; 2012 Dec; 66(8):578-82. PubMed ID: 23085253
[TBL] [Abstract][Full Text] [Related]
6. The early reduction of leukemic blasts in bone marrow on day 6 of induction treatment is predictive for complete remission rate and survival in adult acute myeloid leukemia; the results of multicenter, prospective Polish Adult Leukemia Group study.
Grosicki S; Holowiecki J; Giebel S; Kyrcz-Krzemien S; Kuliczkowski K; Kielbinski M; Skotnicki AB; Piatkowska-Jakubas B; Hellmann A; Wierzbowska A; Stella-Holowiecka B; Zdziarska B; Calbecka M
Am J Hematol; 2011 May; 86(5):437-9. PubMed ID: 21465518
[TBL] [Abstract][Full Text] [Related]
7. Drug resistance in B-cell chronic lymphocytic leukemia: predictable by in vitro evaluation with a multiparameter flow cytometric cytotoxicity assay.
Zhong Y; Bakke AC; Fan G; Braziel RM; Gatter KM; Leis JF; Maziarz RT; Huang JZ
Cytometry B Clin Cytom; 2007 May; 72(3):189-95. PubMed ID: 17226861
[TBL] [Abstract][Full Text] [Related]
8. The use of receiver operating characteristic analysis for detection of minimal residual disease using five-color multiparameter flow cytometry in acute myeloid leukemia identifies patients with high risk of relapse.
Al-Mawali A; Gillis D; Lewis I
Cytometry B Clin Cytom; 2009 Mar; 76(2):91-101. PubMed ID: 18727068
[TBL] [Abstract][Full Text] [Related]
9. Liposomal encapsulation of a synergistic molar ratio of cytarabine and daunorubicin enhances selective toxicity for acute myeloid leukemia progenitors as compared to analogous normal hematopoietic cells.
Kim HP; Gerhard B; Harasym TO; Mayer LD; Hogge DE
Exp Hematol; 2011 Jul; 39(7):741-50. PubMed ID: 21530609
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological purging of minimal residual disease from peripheral blood stem cell collections of acute myeloblastic leukemia patients: preclinical studies.
Motta MR; Mangianti S; Rizzi S; Ratta M; Campanini E; Fortuna A; Fogli M; Tura S; Lemoli RM
Exp Hematol; 1997 Nov; 25(12):1261-9. PubMed ID: 9357970
[TBL] [Abstract][Full Text] [Related]
11. Analysis of the individual and combined reactivities of monoclonal antibodies H25, H366, and MY9 with normal progenitor cells and blast cells from patients with acute myeloblastic leukemia.
Wisniewski D; Strife A; Arlin Z; Knowles R; Lambek C; Gulati S; McHendry B; McKenzie S; Clarkson B
Leukemia; 1989 Jun; 3(6):446-52. PubMed ID: 2657231
[TBL] [Abstract][Full Text] [Related]
12. Increased myeloid precursors in regenerating bone marrow; implications for detection of minimal residual disease in acute myeloid leukemia.
Zeleznikova T; Stevulova L; Kovarikova A; Babusikova O
Neoplasma; 2007; 54(6):471-7. PubMed ID: 17949229
[TBL] [Abstract][Full Text] [Related]
13. Clinical impact of leukemic blast heterogeneity at diagnosis in cytogenetic intermediate-risk acute myeloid leukemia.
Hoffmann MH; Klausen TW; Boegsted M; Larsen SF; Schmitz A; Leinoe EB; Schmiegelow K; Hasle H; Bergmann OJ; Sorensen S; Nyegaard M; Dybkaer K; Johnsen HE
Cytometry B Clin Cytom; 2012 May; 82(3):123-31. PubMed ID: 22328535
[TBL] [Abstract][Full Text] [Related]
14. Absence of aberrant myeloid progenitors by flow cytometry is associated with favorable response to azacitidine in higher risk myelodysplastic syndromes.
Alhan C; Westers TM; van der Helm LH; Eeltink C; Huls G; Witte BI; Buchi F; Santini V; Ossenkoppele GJ; van de Loosdrecht AA
Cytometry B Clin Cytom; 2014 May; 86(3):207-15. PubMed ID: 24474614
[TBL] [Abstract][Full Text] [Related]
15. New strategies for the evaluation of the nadir bone marrow following induction in acute myeloid leukemia.
Mattison RJ; Luger SM; Lazarus HM
Curr Opin Hematol; 2013 Mar; 20(2):93-9. PubMed ID: 23328452
[TBL] [Abstract][Full Text] [Related]
16. Human stem cell factor-antibody [anti-SCF] enhances chemotherapy cytotoxicity in human CD34+ resistant myeloid leukaemia cells.
Lu C; Hassan HT
Leuk Res; 2006 Mar; 30(3):296-302. PubMed ID: 16112192
[TBL] [Abstract][Full Text] [Related]
17. Incidence, sensitivity, and specificity of leukemia-associated phenotypes in acute myeloid leukemia using specific five-color multiparameter flow cytometry.
Al-Mawali A; Gillis D; Hissaria P; Lewis I
Am J Clin Pathol; 2008 Jun; 129(6):934-45. PubMed ID: 18480011
[TBL] [Abstract][Full Text] [Related]
18. Individualized systems medicine strategy to tailor treatments for patients with chemorefractory acute myeloid leukemia.
Pemovska T; Kontro M; Yadav B; Edgren H; Eldfors S; Szwajda A; Almusa H; Bespalov MM; Ellonen P; Elonen E; Gjertsen BT; Karjalainen R; Kulesskiy E; Lagström S; Lehto A; Lepistö M; Lundán T; Majumder MM; Marti JM; Mattila P; Murumägi A; Mustjoki S; Palva A; Parsons A; Pirttinen T; Rämet ME; Suvela M; Turunen L; Västrik I; Wolf M; Knowles J; Aittokallio T; Heckman CA; Porkka K; Kallioniemi O; Wennerberg K
Cancer Discov; 2013 Dec; 3(12):1416-29. PubMed ID: 24056683
[TBL] [Abstract][Full Text] [Related]
19. Addition of PTK787/ZK 222584 can lower the dosage of amsacrine to achieve equal amounts of acute myeloid leukemia cell death.
Weidenaar AC; de Jonge HJ; Fidler V; ter Elst A; Meeuwsen-de Boer T; Douwes J; Bouma-ter Steege JC; Hählen K; Kamps WA; de Bont ES
Anticancer Drugs; 2008 Jan; 19(1):45-54. PubMed ID: 18043129
[TBL] [Abstract][Full Text] [Related]
20. Acute myeloid leukemia: 2013 update on risk-stratification and management.
Estey EH
Am J Hematol; 2013 Apr; 88(4):318-27. PubMed ID: 23526416
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
